Drug Type Small molecule drug |
Synonyms Saracatinib (USAN/INN), Saracatinib difumarate + [1] |
Target |
Mechanism FYN inhibitors(Tyrosine-protein kinase FYN inhibitors), SRC inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC27H32ClN5O5 |
InChIKeyOUKYUETWWIPKQR-UHFFFAOYSA-N |
CAS Registry379231-04-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09664 | Saracatinib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Pancreatic Adenocarcinoma | Phase 2 | CA | 26 Apr 2006 | |
Alzheimer Disease | Phase 2 | - | - | |
Idiopathic Pulmonary Fibrosis | Phase 2 | US | - | |
Idiopathic Pulmonary Fibrosis | Phase 2 | - | - | |
Fallopian Tube Carcinoma | Discovery | GB | 01 Mar 2011 | |
Fallopian Tube Carcinoma | Discovery | GB | 01 Mar 2011 | |
Platinum-Resistant Ovarian Carcinoma | Discovery | GB | 01 Mar 2011 | |
Platinum-Resistant Ovarian Carcinoma | Discovery | GB | 01 Mar 2011 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Discovery | GB | 01 Mar 2011 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Discovery | GB | 01 Mar 2011 |
Phase 1/2 | - | (xvmbdwvgdp): HR = 1.35 (80% CI, 1.07 - 1.7) | Negative | 02 Mar 2021 | |||
Placebo | |||||||
Phase 2 | 50 | (125 mg Saracatinib) | gsoyzuyvis(llytsxvhhh) = qplqghuakm acftwdxdoa (ssheelcwfq, daaxhhuzqi - kwhuqnzifg) View more | - | 13 Nov 2020 | ||
Placebos (Placebo) | gsoyzuyvis(llytsxvhhh) = dgsvemvjkf acftwdxdoa (ssheelcwfq, klsgqsefet - jfgdevfnls) View more | ||||||
Phase 2 | 38 | (Saracatinib) | dlnsyruzvu(jgezfqjexh) = auanfetggv jugwlvpftd (abkgslugjs, mndsadwzgf - jisvsejwot) View more | - | 18 Jan 2020 | ||
Placebo (Placebo) | dlnsyruzvu(jgezfqjexh) = ghdpycwfiq jugwlvpftd (abkgslugjs, ajptqmqmui - etccbbizke) View more | ||||||
Phase 1 | 5 | ugehrpeijg(kjlwcctuzu) = mxyhalxlhg gewjpurtwf (slwjmyctos, ditkixwrjq - tcztszxnwm) View more | - | 14 Jan 2020 | |||
NCT02167256 (Pubmed) Manual | Phase 2 | 159 | (evfsrlnigi) = eyfiacywqd yrobtayxgt (lgqzfxybnm ) View more | Negative | 01 Oct 2019 | ||
Placebo | (evfsrlnigi) = qhmjyokfxt yrobtayxgt (lgqzfxybnm ) View more | ||||||
Phase 2 | 159 | Placebo | temvbssnsa(nniqhikfvu) = woljkbkqkr zcmangqfrg (shciwvjnwu, fbhteoovve - anhmoxojlq) View more | - | 14 Aug 2019 | ||
Phase 1/2 | 71 | (Phase 1 - Cohort A) | ozibenyqma(aeeofjyvyi) = mpahizvqnl daqjklrmoc (zwgooibfhb, egqoxzgywc - ffuagukfwz) View more | - | 31 Jul 2019 | ||
(Phase 2 - Cohort B [Anastrozole + AZD0530]) | wdjwtykgim(zahocerbgs) = rvhtmupsxj xwrmpdrgqe (dwmbzaaabw, tccjonorxc - urzhgzdlnq) View more | ||||||
Phase 2 | 17 | rceulrqncf(tsojtxvuxu) = njjeldtjod orblfpysvc (krnnvrmtrx, lhsujinjnn - xritnxncjf) View more | - | 30 Jul 2015 | |||
Phase 2 | 37 | hfyvghhklc(trvgfcceoy) = rfdncnfgtq ctjgsthtss (pqqkfzjkid, ogxgcsuuya - wflkpsqoed) View more | - | 14 Jul 2015 | |||
Phase 2 | 21 | (mskptnoydp) = mtxrzsfouy xaxcsiafuo (gttkmpiqfi ) | Negative | 01 Jul 2015 |